胰腺癌是全球癌症相关死亡的第八大原因。化疗包括吉西他滨、5-氟尿嘧啶、阿霉素和顺铂，免疫治疗包括免疫检查点抑制剂和靶向治疗已经被证明能显著改善晚期胰腺癌患者的预后。然而，大多数患者会对这些治疗药物产生耐药性，从而导致患者的生存期缩短。对于导致胰腺癌耐药性的详细分子机制仍然不清楚。越来越多的证据表明，非编码RNA（ncRNAs），包括microRNAs（miRNAs），长非编码RNA（lncRNAs）和环状RNA（circRNAs），参与了胰腺癌发病机制和药物耐药性的发展。在本综述中，我们系统地总结了miRNAs，lncRNAs和circRNAs对胰腺癌药物耐药性的新见解。这些结果表明，靶向肿瘤特异性ncRNA可能为胰腺癌治疗提供新的选择。版权所有©2023年Wei，Sun，Wang，Huang，Huang，Han，Zheng，Xu，Zhang和杨。

Pancreatic cancer is the eighth leading cause of cancer-related deaths worldwide. Chemotherapy including gemcitabine, 5-fluorouracil, adriamycin and cisplatin, immunotherapy with immune checkpoint inhibitors and targeted therapy have been demonstrated to significantly improve prognosis of pancreatic cancer patients with advanced diseases. However, most patients developed drug resistance to these therapeutic agents, which leading to shortened patient survival. The detailed molecular mechanisms contributing to pancreatic cancer drug resistance remain largely unclear. The growing evidences have shown that noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are involved in pancreatic cancer pathogenesis and development of drug resistance. In the present review, we systematically summarized the new insight on of various miRNAs, lncRNAs and circRNAs on drug resistance of pancreatic cancer. These results demonstrated that targeting the tumor-specific ncRNA may provide novel options for pancreatic cancer treatments.Copyright © 2023 Wei, Sun, Wang, Huang, Huang, Han, Zheng, Xu, Zhang and Yang.